HitGen Inc.

HitGen Inc.

生物技术研究

Chengdu,Sichuan 3,143 位关注者

Looking for new molecules? ask HitGen!

关于我们

HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com

网站
http://www.hitgen.com
所属行业
生物技术研究
规模
201-500 人
总部
Chengdu,Sichuan
类型
上市公司
创立
2012
领域
Hit identification、Lead generation、Chemical library synthesis、Early phase R&D、Protein production and purification、DNA encoded libraries、Hit expansion libraries、Screening libraries、Drug Discovery、synthetic therapeutic oligonucleotide、 fragment-based drug discovery、 structure-based drug design、E3 ligases、targeted protein degradation 和new molecular entities

地点

  • 主要

    Building 6, No. 8 Huigu 1st East Road

    Tianfu International Bio-Town Shuangliu District

    CN,Sichuan,Chengdu,610200

    获取路线

HitGen Inc.员工

动态

  • 查看HitGen Inc.的公司主页,图片

    3,143 位关注者

    🎉🎉The countdown to our amazing webinar continues! 🎉🎉 Only 12 hours left until we gather to share insights on DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery! 📅 Our webinar will be held on Wednesday, July 17, 2024 at 2pm EDT/1pm CDT/11am PDT(60min) Everyone is warmly invited to participated in our webinar! Register now: https://lnkd.in/gDmCd3yH Can't wait to see you all there! 🌟 #ComingSoon #Webinar #Xtalks #HitGen #DEL #DELfor #OpenDEL

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看HitGen Inc.的公司主页,图片

    3,143 位关注者

    🎤 Meet Our Webinar Speaker: Dr. David Israel Can't wait to introduce our last distinguished speaker for our upcoming webinar, Dr. David Israel, who holds a PhD and VP of Lead Discovery Sciences at HitGen. He will discuss DEL selection on different target types ranging from enzymes to receptors. 📅 Our webinar will be held on Wednesday, July 17, 2024 at 2pm EDT/1pm CDT/11am PDT(60min) 🔹 About Dr. David Israel: Dr. David Israel is the Vice President of Lead Discovery Sciences at HitGen Inc., supervising the advancement of the DNA Encoded Library (DEL) platform and its application in drug discovery programs. He got his Ph.D. in Pharmacology from Stanford University in 1984. Dr. Israel began his industrial career at Genetics Institute (now Pfizer), then worked at PRAECIS Pharmaceuticals. Before joining HitGen in 2018, he worked at GSK. Dr. Israel was the scientific leader of the first DEL project that produced a molecule progressing into clinical trials, an inhibitor of the enzyme soluble epoxide hydrolase. 🔗 Want to know his unique viewpoint in drug discovery? Register now: https://lnkd.in/gDmCd3yH We' re only two days away! Secure your spot today and get ready for this must-attend event! #Webinar #IndustryExperts #ProfessionalDevelopment #Xtalks #HitGen #DEL #DELfor #OpenDEL

    • 该图片无替代文字
  • 查看HitGen Inc.的公司主页,图片

    3,143 位关注者

    🎤 Meet Our Webinar Speaker: Dr. Rusty Montgomery Let's introduce another distinguished speaker for our upcoming webinar, Dr. Rusty Montgomery, who holds a PhD and is the SVP of Research at BioAge Labs. He will discuss groundbreaking discoveries of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening. 📅 Our webinar will be held on Wednesday, July 17, 2024 at 2pm EDT/1pm CDT/11am PDT(60min) 🔹 About Dr. Rusty Montgomery: Dr. Montgomery brings over 12 years of experience in target discovery across various therapeutic areas. Before joining BioAge, he was the Director of Research at miRagen Therapeutics, focusing on preclinical efforts and alliance management in cardiovascular and fibrotic diseases. He has 25 publications and 9 patents related to RNA and epigenetic modifiers as therapeutics in cardiovascular, fibrosis, and neurological diseases. Dr. Montgomery received his BS in Biochemistry from the University of Oklahoma and completed his PhD and postdoctoral work in Genetics at the University of Texas Southwestern Medical Center. 🔗 Want to know his unique viewpoint in drug discovery? Register now: https://lnkd.in/gDmCd3yH We' re only five days away! Secure your spot today and get ready for this must-attend event! #Webinar #IndustryExperts #ProfessionalDevelopment #Xtalks #HitGen #DEL #DELfor #OpenDEL

    • 该图片无替代文字
  • 查看HitGen Inc.的公司主页,图片

    3,143 位关注者

    🎤 Meet Our Webinar Speaker: Dr. Alex Shaginian, PhD, MBA Shaginian We are excited to introduce one of our esteemed speakers for the upcoming webinar, Dr. Alex Shaginian, PhD, MBA Shaginian, who holds a PhD and is the VP of Business Development and Chemical Sciences at HitGen. He will share insights on Development and Application of DNA-encoded library (DEL) technology to small Molecule Drug Discovery. 📅 Our webinar will be held on Wednesday, July 17, 2024 at 2pm EDT/1pm CDT/11am PDT(60min) 🔹 About Dr. Alex Shaginian: Dr. Alex Shaginian holds a PhD in organic chemistry from the University of Wisconsin-Madison and an MBA in finance and strategy from Babson's F.W. Olin Graduate School of Business. He began his career as a Senior Scientist in medicinal chemistry at Ardea Biosciences and later joined GSK as a Principal Scientist, specializing in DNA-encoded library (DEL) technology. At HitGen, he leads business development and chemical sciences, focusing on negotiating deals, forming partnerships, and analyzing DEL selection results. Alex has co-authored over 15 scientific publications and patents. 🔗 Want to know his unique viewpoint in drug discovery? Register now: https://lnkd.in/gDmCd3yH Stay tuned for more updates about our speakers and what you can expect from this must-attend event! #Webinar #IndustryExperts #ProfessionalDevelopment #Xtalks #HitGen #DEL #DELfor #OpenDEL

    • 该图片无替代文字
  • 查看HitGen Inc.的公司主页,图片

    3,143 位关注者

    🌟 Join Our Upcoming Webinar: Unlocking the Future of Application of DNA-Encoded Library Technology in Drug Discovery🌟 Are you ready to take your knowledge to the next level? We are thrilled to invite you to our exclusive webinar on Wednesday, July 17, 2024 at 2pm EDT/1pm CDT/11am PDT(60min) 🔍 What You'll Learn: - Various DNA-Encoded Library platforms and strategic uses in drug discovery - DNA-Encoded Library technology - Case study insights on novel inhibitor discovery 🎤 Meet Our Speakers: - Alex Shaginian, PhD, VP of Business Development and Chemical Sciences at HitGen - Rusty Montgomery, PhD, SVP-Research at BioAge Labs - David Israel, PhD, VP of Lead Discovery Sciences at HitGen 🌐 Why Attend: - Engage with industry experts - Gain actionable insights - Network with like-minded professionals 📅 Save the Date: Wednesday, July 17, 2024 🕒 Time: 2pm EDT/1pm CDT/11am PDT(60min) 💻 Register Now: https://lnkd.in/gDmCd3yH Don't miss out on this opportunity to stay ahead in the ever-evolving world of Drug Discovery. Register today for free and secure your spot! #Webinar #IndustryTrends #ProfessionalDevelopment #Networking #Innovation #HitGen

    • 该图片无替代文字
  • 查看HitGen Inc.的公司主页,图片

    3,143 位关注者

    We are excited to announce a series of exhilarating #sports events for 2024, featuring our thrilling #basketball tournament, strategic #badminton matches, and fast-paced #tabletennis games! At #HitGen, we are dedicated to our vision of becoming a world-class innovative #biopharmaceutical company and our mission to develop #newdrugs that alleviate human suffering. We strive to create a vibrant, positive work environment that inspires and energizes our employees. Join us and be part of our dynamic community!

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看HitGen Inc.的公司主页,图片

    3,143 位关注者

    We're excited to share that the Lead Pharma 2024 Badminton Tournament was a smashing success! This year's event saw seven amazing teams battle it out on the court. Huge congratulations to our champions! We can't wait to see even more of you joining our future club activities. Your ideas and suggestions for our sports programs are always welcome – let's keep the energy high and the community thriving. Stay active and see you at our next event! #HitGen #EnterpriseCulture #Badminton

    • 该图片无替代文字
    • 该图片无替代文字

相似主页

融资